logo

For the Inventor, By the Inventor

Seattle, WA, United States of America

Omeros Corporation


USPTO Granted Patents = 99

% Expired Patents = 11.1



Trademarks = 17

Forward Citations = 807

Loading Chart...
Loading Chart...

113 inventors (with patents filed for the assignee):

goldMedal Gregory A Demopulos (47 out of 65 patents)

silverMedal Thomas Dudler (23 out of 24 patents)

bronzeMedal Neil S Cutshall (23 out of 24 patents)

4.  Jennifer Lynn Gage (20 out of 36 patents)

5.  Hans-Wilhelm Schwaeble (16 out of 19 patents)

6.  Jeffrey M Herz (15 out of 27 patents)

7.  Munehisa Yabuki (12 out of 15 patents)

8.  Clark E Tedford (12 out of 18 patents)

9.  Thomas L Little, Jr (12 out of 29 patents)

10.  Larry W Tjoelker (11 out of 25 patents)

11.  W Jason Cummings (10 out of 13 patents)

12.  Wayne Richard Gombotz (9 out of 20 patents)

13.  Christi L Wood (9 out of 9 patents)

14.  James Brian Parent (9 out of 14 patents)

15.  Peter Kurt Nollert Von Specht (9 out of 10 patents)


Core Competencies:
MASP-2 Inhibitors
Therapeutic Antibodies
Complement Activation
Graft-Versus-Host Disease
PDE10 Inhibitors
Fibrosis Treatment
Ocular Inflammation
Addiction Treatment
Chimeric Inhibitors
Monoclonal Antibodies
Optically Active Compounds
Bioactive Peptides

99 patents:

1. 12703684 - MASP-2 INHIBITORS AND METHODS OF USE (2026-08-11),
2. 12692229 - MASP-2 INHIBITORS AND METHODS OF USE (2026-07-28),
3. 12351648 - Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome (2025-07-08),
4. 12195427 - MASP-2 inhibitors and methods of use (2025-01-14),
5. 12129290 - Monoclonal antibodies, compositions and methods for detecting complement factor D (2024-10-29),
6. 12110288 - MASP-2 inhibitors and methods of use (2024-10-08),
7. 12091468 - Therapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereof (2024-09-17),
8. 12030853 - MASP-2 inhibitors and methods of use (2024-07-09),
9. 12005117 - Methods for inhibiting fibrosis in a subject in need thereof (2024-06-11),
10. 11981749 - Methods for treating conditions associated with MASP-2 dependent complement activation (2024-05-14),
11. 11981748 - Methods for inhibiting angiogenesis in a subject in need thereof (2024-05-14),
12. 11945848 - Chimeric inhibitor molecules of complement activation (2024-04-02),
13. 11896621 - Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant (2024-02-13),
14. 11884742 - Methods for treating conditions associated with MASP-2 dependent complement activation (2024-01-30),
15. 11883493 - Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders (2024-01-30),
Omeros Corporation is a biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative therapeutics. With a focus on addressing unmet medical needs, Omeros has developed a diverse pipeline of product candidates targeting various indications, including inflammation, central nervous system disorders, and immune system disorders. The company is committed to improving patient outcomes through its research and development efforts.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Omeros Corporation
99 Patents

#22 in Seattle, WA

#67 in Washington

#3,819 in US

#7,837 in the World

Seattle, WA (US)
Seattle, WA, United States of America

Omeros Corporation

Forward Citations = 807

113 inventors:

goldMedal Gregory A Demopulos (47 out of 65 patents)

silverMedal Thomas Dudler (23 out of 24 patents)

bronzeMedal Neil S Cutshall (23 out of 24 patents)

4.  Jennifer Lynn Gage (20 out of 36 patents)

5.  Hans-Wilhelm Schwaeble (16 out of 19 patents)

Please report any incorrect information to [email protected]
Loading…